Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 14/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL658089 | 0.93 | HSP90AA1 (0.51) | SMYD3HSP90AA1HSP90AB1ACKR3 | |
| SCHEMBL658893 | 0.92 | HSP90AA1 (0.52) | SMYD3HSP90AA1HSP90AB1 | |
| SCHEMBL658894 | 0.92 | HSP90AA1 (0.52) | SMYD3HSP90AA1HSP90AB1 | |
| SCHEMBL656633 | 0.85 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1ACKR3 | |
| SCHEMBL656277 | 0.78 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1ACKR3 | |
| SCHEMBL656360 | 0.77 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1 | |
| SCHEMBL16354260 | 0.74 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1 | |
| SCHEMBL16354261 | 0.74 | HSP90AA1 (0.75) | HSP90AA1HSP90AB1 | |
| SCHEMBL657886 | 0.69 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1 | |
| SCHEMBL16388043 | 0.69 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993556-B2 | Resorcinol derivatives as HSP90 inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-31 | — | — | US | disclosed |
| EP-2421833-B1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-01-14 | — | — | EP | disclosed |
| EP-2421833-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-02-23 | — | — | US | disclosed |
| WO-2010121963-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046266-A1 | RESORCINOL DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90AB2P | SMYD3 2991/4885HSP90AA1 2/4885HSP90AB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.